<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20031101//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS Comput Biol</journal-id><journal-id journal-id-type="iso-abbrev">PLoS Comput. Biol</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">ploscomp</journal-id><journal-title-group><journal-title>PLoS Computational Biology</journal-title></journal-title-group><issn pub-type="ppub">1553-734X</issn><issn pub-type="epub">1553-7358</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">2727484</article-id><article-id pub-id-type="pmid">19701464</article-id><article-id pub-id-type="publisher-id">09-PLCB-RA-0379R2</article-id><article-id pub-id-type="doi">10.1371/journal.pcbi.1000474</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline"><subject>Chemical Biology/Small Molecule Chemistry</subject><subject>Computational Biology/Metabolic Networks</subject><subject>Computational Biology/Metagenomics</subject><subject>Computational Biology/Systems Biology</subject><subject>Genetics and Genomics</subject><subject>Genetics and Genomics/Comparative Genomics</subject><subject>Infectious Diseases</subject><subject>Pharmacology</subject><subject>Pharmacology/Drug Development</subject></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>A Mapping of Drug Space from the Viewpoint of Small Molecule Metabolism </plain></SENT>
</text></SecTag></article-title><alt-title alt-title-type="running-head">Drug Discovery in Small Molecule
Metabolism</alt-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Adams</surname><given-names>James Corey</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Keiser</surname><given-names>Michael J.</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Basuino</surname><given-names>Li</given-names></name><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Chambers</surname><given-names>Henry F.</given-names></name><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Deok-Sun</given-names></name><xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref><xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref><xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Wiest</surname><given-names>Olaf G.</given-names></name><xref ref-type="aff" rid="aff7">
<sup>7</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Babbitt</surname><given-names>Patricia C.</given-names></name><xref ref-type="aff" rid="aff8">
<sup>8</sup>
</xref><xref ref-type="aff" rid="aff9">
<sup>9</sup>
</xref><xref ref-type="aff" rid="aff10">
<sup>10</sup>
</xref><xref ref-type="corresp" rid="cor1">
<sup>*</sup>
</xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>Graduate Program in Pharmaceutical Sciences and Pharmacogenomics,
University of California, San Francisco, California, United States of
America</addr-line></aff><aff id="aff2"><label>2</label><addr-line>Graduate Program in Bioinformatics, University of California, San
Francisco, California, United States of America</addr-line></aff><aff id="aff3"><label>3</label><addr-line>San Francisco General Hospital, University of California San Francisco,
San Francisco, California, United States of America</addr-line></aff><aff id="aff4"><label>4</label><addr-line>Center for Complex Network Research and Departments of Physics, Biology,
and Computer Science, Northeastern University, Boston, Massachusetts, United
States of America</addr-line></aff><aff id="aff5"><label>5</label><addr-line>Center for Cancer Systems Biology, Dana-Farber Cancer Institute, Boston,
Massachusetts, United States of America</addr-line></aff><aff id="aff6"><label>6</label><addr-line>Department of Natural Medical Sciences, Inha University, Incheon,
Korea</addr-line></aff><aff id="aff7"><label>7</label><addr-line>Department of Chemistry and Biochemistry, University of Notre Dame, Notre
Dame, Indiana, United States of America</addr-line></aff><aff id="aff8"><label>8</label><addr-line>Department of Bioengineering and Therapeutic Sciences, University of
California, San Francisco, California, United States of America</addr-line></aff><aff id="aff9"><label>9</label><addr-line>Department of Pharmaceutical Chemistry, University of California, San
Francisco, California, United States of America</addr-line></aff><aff id="aff10"><label>10</label><addr-line>California Institute for Quantitative Biosciences, University of
California, San Francisco, California, United States of America</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Bourne</surname><given-names>Philip E.</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">University of California San Diego, United States of America</aff><author-notes><corresp id="cor1">* E-mail: <email>Babbitt@cgl.ucsf.edu</email></corresp><fn fn-type="con"><p><text><SENT sid="1" pm="."><plain>Conceived and designed the experiments: JCA MJK OGW PCB. </plain></SENT>
<SENT sid="2" pm="."><plain>Performed the experiments: JCA MJK LB. </plain></SENT>
<SENT sid="3" pm="."><plain>Analyzed the data: JCA OGW. </plain></SENT>
<SENT sid="4" pm="."><plain>Contributed reagents/materials/analysis tools: MJK D-SL HFC. </plain></SENT>
<SENT sid="5" pm="."><plain>Wrote the paper: JCA PCB. </plain></SENT>
</text></p></fn></author-notes><pub-date pub-type="collection"><month>8</month><year>2009</year></pub-date><pub-date pub-type="epub"><day>21</day><month>8</month><year>2009</year></pub-date><volume>5</volume><issue>8</issue><elocation-id>e1000474</elocation-id><history><date date-type="received"><day>9</day><month>4</month><year>2009</year></date><date date-type="accepted"><day>16</day><month>7</month><year>2009</year></date></history><permissions><copyright-statement>Adams et al.</copyright-statement><copyright-year>2009</copyright-year><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.</license-p></license></permissions><abstract><p><SecTag type="ABS"><text><SENT sid="6" pm="."><plain>Small molecule drugs target many core metabolic enzymes in humans and pathogens, often mimicking endogenous ligands. </plain></SENT>
<SENT sid="7" pm="."><plain>The effects may be therapeutic or toxic, but are frequently unexpected. </plain></SENT>
<SENT sid="8" pm="."><plain>A large-scale mapping of the intersection between drugs and metabolism is needed to better guide drug discovery. </plain></SENT>
<SENT sid="9" pm="."><plain>To map the intersection between drugs and metabolism, we have grouped drugs and metabolites by their associated targets and enzymes using ligand-based set signatures created to quantify their degree of similarity in chemical space. </plain></SENT>
<SENT sid="10" pm="."><plain>The results reveal the chemical space that has been explored for metabolic targets, where successful drugs have been found, and what novel territory remains. </plain></SENT>
<SENT sid="11" pm="."><plain>To aid other researchers in their drug discovery efforts, we have created an online resource of interactive maps linking drugs to metabolism. </plain></SENT>
<SENT sid="12" pm="."><plain>These maps predict the “effect space” comprising likely target enzymes for each of the 246 MDDR drug classes in humans. </plain></SENT>
<SENT sid="13" pm="."><plain>The online resource also provides species-specific interactive drug-metabolism maps for each of the 385 model organisms and pathogens in the BioCyc database collection. </plain></SENT>
<SENT sid="14" pm="."><plain>Chemical similarity links between drugs and metabolites predict potential toxicity, suggest routes of metabolism, and reveal drug polypharmacology. </plain></SENT>
<SENT sid="15" pm="."><plain>The metabolic maps enable interactive navigation of the vast biological data on potential metabolic drug targets and the drug chemistry currently available to prosecute those targets. </plain></SENT>
<SENT sid="16" pm="."><plain>Thus, this work provides a large-scale approach to ligand-based prediction of drug action in small molecule metabolism. </plain></SENT>
</text></SecTag></p></abstract><abstract abstract-type="summary"><title><text><SENT sid="17" pm="."><plain>Author Summary </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="18" pm="."><plain>All humans, plants, and animals use enzymes to metabolize food for energy, build and maintain the body, and get rid of toxins. </plain></SENT>
<SENT sid="19" pm="."><plain>Drugs used to clear infections or cure cancer often target enzymes in bacteria or cancer cells, but the drugs can interfere with the proper function of human enzymes as well. </plain></SENT>
<SENT sid="20" pm="."><plain>Recent studies have mapped drugs to enzymes and many other targets in humans and other organisms, but have not focused on metabolism. </plain></SENT>
<SENT sid="21" pm="."><plain>In this study, we present a new method to predict what enzymes drugs might affect based on the chemical similarity between classes of drugs and the natural chemicals used by enzymes. </plain></SENT>
<SENT sid="22" pm="."><plain>We have applied the method to 246 known drug classes and a collection of 385 organisms (including 65 National Institutes of Health Priority Pathogens) to create maps of potential drug action in metabolism. </plain></SENT>
<SENT sid="23" pm="."><plain>We also show how the predicted connections can be used to find new ways to kill pathogens and to avoid unintentionally interfering with human enzymes. </plain></SENT>
</text></SecTag></p></abstract><counts><page-count count="12"/></counts></article-meta></front><body><SecTag type="INTRO"><sec id="s1"><title><text><SENT sid="24" pm="."><plain>Introduction </plain></SENT>
</text></title><p><text><SENT sid="25" pm="."><plain>Drug developers have long mined small molecule metabolism for new drug targets and chemical strategies for inhibition. </plain></SENT>
<SENT sid="26" pm="."><plain>The approach leverages the “chemical similarity principle” [1] which states that similar molecules likely have similar properties. </plain></SENT>
<SENT sid="27" pm="."><plain>Applied to small molecule metabolism, this principle has motivated the search for enzyme inhibitors chemically similar to their endogenous substrates. </plain></SENT>
<SENT sid="28" pm="."><plain>The approach has yielded many successes, including antimetabolites such as the folate derivatives used in cancer therapy and the nucleoside analog pro-drugs used for antiviral therapy. </plain></SENT>
<SENT sid="29" pm="."><plain>However, drug discovery efforts also frequently falter due to unacceptable metabolic side-effect profiles or incomplete genomic information for poorly characterized pathogens [2]–[4]. </plain></SENT>
</text></p><p><text><SENT sid="30" pm="."><plain>With the recent availability of large datasets of drugs and drug-like molecules, computational profiling of small molecules has been performed to create global maps of pharmacological activity. </plain></SENT>
<SENT sid="31" pm="."><plain>This in turn provides a larger context for evaluation of metabolic targets. </plain></SENT>
<SENT sid="32" pm="."><plain>For example, Paolini et al. [5] identified 727 human drug targets associated with ligands exhibiting potency at concentrations below 10 µM, thereby creating a polypharmacology interaction network organized by the similarity between ligand binding profiles. </plain></SENT>
<SENT sid="33" pm="."><plain>Keiser et al. [6] organized known drug targets into biologically sensible clusters based solely upon the bond topology of 65,000 biologically active ligands. </plain></SENT>
<SENT sid="34" pm="."><plain>The results revealed new and unexpected pharmacological relationships, three of which involved GPCRs and their predicted ligands that were subsequently confirmed in vitro. </plain></SENT>
<SENT sid="35" pm="."><plain>Cleves et al. [7] also rationalized several known drug side effects and drug-drug interactions based upon three-dimensional modeling of 979 approved drugs. </plain></SENT>
<SENT sid="36" pm="."><plain>However, despite the clear rationale and past successes in applying ligand-based approaches to drug discovery, global mapping between drugs and small molecule metabolism, the goal of this study, has been hindered by both methodological challenges and incomplete genomic information. </plain></SENT>
<SENT sid="37" pm="."><plain>The relatively recent availability of metabolomes for numerous organisms allows a fresh look on a large scale [8]–[13]. </plain></SENT>
</text></p><p><text><SENT sid="38" pm="."><plain>In this work, we link the chemistry of drugs to the chemistry of small molecule metabolites to investigate the intersection between small molecule metabolism and drugs. </plain></SENT>
<SENT sid="39" pm="."><plain>The Similarity Ensemble Approach (SEA) [6] was used to link metabolic reactions and drug classes by their chemical similarity, measured by comparing bond topology patterns between sets of molecules. </plain></SENT>
<SENT sid="40" pm="."><plain>Two types of molecule sets are used in this work. </plain></SENT>
<SENT sid="41" pm="."><plain>The first comprises drug-like molecules known to act at a specific protein target, and the second comprises the known substrates and products of an enzymatic reaction. </plain></SENT>
<SENT sid="42" pm="."><plain>While this approach is complementary to target and disease focused methods [5], [14]–[23], neither protein structure nor sequence information is used in the comparisons. </plain></SENT>
<SENT sid="43" pm="."><plain>Thus, these links provide an orthogonal view of metabolism based only upon the chemical similarity between existing drug classes and endogenous metabolites. </plain></SENT>
</text></p><p><text><SENT sid="44" pm="."><plain>To provide the results in the context of metabolism, drug “effect-space” maps were also created. </plain></SENT>
<SENT sid="45" pm="."><plain>For each of the 246 drug classes investigated in this work, effect-space maps enable visualization of the chemical similarities between drugs and metabolites painted onto human metabolic pathways, allowing a unique assessment of potential drug action in humans. </plain></SENT>
<SENT sid="46" pm="."><plain>In addition, to aid target discovery in pathogens, 385 species-specific effect-space maps were created to show the predicted effect-space of currently marketed drugs, painted onto metabolic pathways representing target reactions in model organisms and pathogens. </plain></SENT>
<SENT sid="47" pm="."><plain>Examples of these maps are provided below and their applications in predicting drug action, toxicity, and routes of metabolism are discussed. </plain></SENT>
<SENT sid="48" pm="."><plain>To enable facile exploration of the drug-metabolite links established by this analysis, interactive versions of both sets of maps are available at <ext-link ext-link-type="uri" xlink:href="http://sea.docking.org/metabolism">http://sea.docking.org/metabolism</ext-link>. </plain></SENT>
</text></p><p><text><SENT sid="49" pm="."><plain>Finally, using methicillin-resistant Staphylococcus aureus (MRSA), a major pathogen causing both hospital- and community-acquired infections that is resistant to at least one of the antibiotics most commonly used for treatment [24]–[28] as an example, we show by retrospective analysis the use of species-specific maps for discovery and evaluation of drug targets. </plain></SENT>
<SENT sid="50" pm="."><plain>This also illustrates how additional types of biological information can be incorporated to enhance the value of these analyses. </plain></SENT>
</text></p></sec></SecTag><SecTag type="RESULTS"><sec id="s2"><title><text><SENT sid="51" pm="."><plain>Results </plain></SENT>
</text></title><sec id="s2a"><title><text><SENT sid="52" pm="."><plain>Drug-metabolite links reproduce known drug-target interactions </plain></SENT>
</text></title><p><text><SENT sid="53" pm="."><plain>To evaluate the chemical similarity between drug classes and metabolic reactions, links between sets of metabolic ligands and sets of drugs were generated according to SEA ( Figure 1 ) [6]. </plain></SENT>
<SENT sid="54" pm="."><plain>The similarity metric consists of a descriptor, represented by standard two-dimensional topological fingerprints, and a similarity criterion, the Tanimoto coefficient (Tc). </plain></SENT>
<SENT sid="55" pm="."><plain>Expectation (E) values were calculated for each set pair by comparing the raw scores to a background distribution generated using sets of randomly selected molecules (see  Methods  for further details). </plain></SENT>
<SENT sid="56" pm="."><plain>To represent metabolic ligand sets, the MetaCyc database, which includes enzymes from more than 900 different organisms catalyzing over 6,000 reactions, was used [12]. </plain></SENT>
<SENT sid="57" pm="."><plain>The substrates and products of each enzymatic reaction were combined to form a reaction set, each of which was required to contain at least two unique compounds ( Datasets S1  and  S2 ). </plain></SENT>
<SENT sid="58" pm="."><plain>Ubiquitous molecules called common carriers, which frequently play critical roles in reaction chemistry but do not distinguish the function of a specific enzyme, were removed, leaving a total of 5,056 reactions involving 4,998 unique compounds. </plain></SENT>
<SENT sid="59" pm="."><plain>To represent drugs, a subset of 246 targets of the MDL Drug Data Report (MDDR) collection, which annotates ligands according to the targets they modulate, was used ( Datasets S3  and  S4 ) [30]. </plain></SENT>
<SENT sid="60" pm="."><plain>These sets contain 65,241 unique ligands with a median and mean of 124 and 289 ligands per target, respectively. </plain></SENT>
<SENT sid="61" pm="."><plain>Overall, 246 drug versus 5,056 reaction set comparisons involving 1.39×109 pairwise comparisons were made. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="pcbi-1000474-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1000474.g001</object-id><label>Figure 1</label><caption><title><text><SENT sid="62" pm="."><plain>Similarity Ensemble Approach (SEA). </plain></SENT>
</text></title><p><text><SENT sid="63" pm="."><plain>SEA compares groups of ligands based upon bond topology. </plain></SENT>
<SENT sid="64" pm="."><plain>Example ligand sets include the thymidylate synthase reaction set, composed of the reaction substrates and products, and the nucleotide reverse transcriptase inhibitor (NRTI) drug set, which includes known inhibitors of the nucleoside reverse transcriptase enzyme. </plain></SENT>
<SENT sid="65" pm="."><plain>Fingerprints representing the bond topology of each molecule are generated. </plain></SENT>
<SENT sid="66" pm="."><plain>Raw scores between sets are calculated based upon Tanimoto coefficients between fingerprints for all molecule pairs. </plain></SENT>
<SENT sid="67" pm="."><plain>Finally, the raw scores are compared to a background distribution to determine the expectation value (E) representing the chemical similarity between sets. </plain></SENT>
<SENT sid="68" pm="."><plain>See Methods for further details. </plain></SENT>
</text></p></caption><graphic xlink:href="pcbi.1000474.g001"/></fig></SecTag><p><text><SENT sid="69" pm="."><plain>Although drugs and metabolites typically differ in their physiochemical properties, significant and specific similarity links nonetheless emerged. </plain></SENT>
<SENT sid="70" pm="."><plain>Using SEA at an expectation value cutoff of E = 1.0×10−10, a previously reported cutoff for significance [6], 54% (132 of 246) of drug sets link to an average of 43.7 (median = 10) or 0.9% of metabolic reactions. </plain></SENT>
<SENT sid="71" pm="."><plain>None of the remaining 46% (114 of 246) of drug sets link to any metabolic reaction sets. </plain></SENT>
<SENT sid="72" pm="."><plain>For instance, while the α-glucosidase drug set links to the α-glucosidase reaction (E = 1.00×10−51), the thrombin inhibitor drug set does not link significantly with any metabolic reaction. </plain></SENT>
<SENT sid="73" pm="."><plain>The thrombin inhibitor drug set targets the serine protease thrombin, which does not participate in small molecule metabolism, but rather plays a role in the coagulation signaling cascade. </plain></SENT>
<SENT sid="74" pm="."><plain>Likewise, 40% (2,044 of 5,056) of metabolic reactions hit an average of 2.8 (median = 2) or 1.1% of drug sets at expectation value E = 1.0×10−10 or better. </plain></SENT>
<SENT sid="75" pm="."><plain>For instance, the metabolite set for retinal dehydrogenase reaction set links, as expected, to the retinoid drugs at E = 3.05×E−98, but the valine decarboxylase reaction, which is not an MDDR drug target, does not link significantly to any drug sets. </plain></SENT>
<SENT sid="76" pm="."><plain>These strikingly similar results suggest both broad coverage (54% of drug sets and 40% of metabolite sets) and specificity (single sets link to just 0.9% of metabolite sets and 1.1% of drug sets, respectively). </plain></SENT>
<SENT sid="77" pm="."><plain>For full results, see  Dataset S5 . </plain></SENT>
</text></p><p><text><SENT sid="78" pm="."><plain>To determine the utility of the method for recovery of known drug-target interactions, it was hypothesized that chemical similarity between MetaCyc reaction sets and corresponding MDDR drug sets could specifically recover the known drug-target interactions. </plain></SENT>
<SENT sid="79" pm="."><plain>The 246 MDDR drug set targets include 62 enzymes that could be mapped to MetaCyc via the Enzyme Commission (EC) number [31] describing the overall reaction catalyzed [32]. </plain></SENT>
<SENT sid="80" pm="."><plain>The results show that all 62 reaction sets for these targets link to at least one MDDR drug set. </plain></SENT>
<SENT sid="81" pm="."><plain>The majority of best hits (42 out of 62) were found at expectation values of E = 1.0×10−10 or better ( Table 1 ). </plain></SENT>
<SENT sid="82" pm="."><plain>At expectation values better than E = 1.0×10−25, 61% (19 of 31) of best hits recover either the specific known target or another enzyme in the same pathway. </plain></SENT>
<SENT sid="83" pm="."><plain>Examples of specific compounds linked by this analysis are given in  Figure 2  for a selected group of these best-scoring hits. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="pcbi-1000474-g002" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1000474.g002</object-id><label>Figure 2</label><caption><title><text><SENT sid="84" pm="."><plain>Selected best hits between MetaCyc reaction sets and MDDR drug sets. </plain></SENT>
</text></title></caption><graphic xlink:href="pcbi.1000474.g002"/></fig></SecTag><SecTag type="TABLE"><table-wrap id="pcbi-1000474-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1000474.t001</object-id><label>Table 1</label><caption><title><text><SENT sid="85" pm="."><plain>Metabolic enzyme targets and their best links to MDDR. </plain></SENT>
</text></title></caption><alternatives><graphic id="pcbi-1000474-t001-1" xlink:href="pcbi.1000474.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="86" pm="."><plain>Enzyme Targeta </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="87" pm="."><plain>EC# </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="88" pm="."><plain>Best Hit MDDR Drug Set </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="89" pm="."><plain>Best Hit E-value </plain></SENT>
</text></td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="90" pm="."><plain>Adenosine kinase </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="91" pm="."><plain>2.7.1.20 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="92" pm="."><plain>S-Adenosyl-L-Homocysteine Hydrolase Inhibitor </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="93" pm="."><plain>4.38E-288 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="94" pm="."><plain>Adenosylmethionine decarboxylase </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="95" pm="."><plain>4.1.1.50 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="96" pm="."><plain>S-Adenosyl-L-Homocysteine Hydrolase Inhibitor </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="97" pm="."><plain>2.71E-216 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="98" pm="."><plain>Thromboxane-A synthase </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="99" pm="."><plain>5.3.99.5 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="100" pm="."><plain>Prostaglandin </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="101" pm="."><plain>1.66E-204 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="102" pm="."><plain>Adenosylhomocysteinase </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="103" pm="."><plain>3.3.1.1 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="104" pm="."><plain>S-Adenosyl-L-Homocysteine Hydrolase Inhibitor </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="105" pm="."><plain>4.73E-203 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="106" pm="."><plain>Adenosine deaminase </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="107" pm="."><plain>3.5.4.4 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="108" pm="."><plain>Adenosine (A1) Agonist </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="109" pm="."><plain>7.69E-159 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="110" pm="."><plain>Thymidine kinase </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="111" pm="."><plain>2.7.1.21 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="112" pm="."><plain>Thymidine Kinase Inhibitor </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="113" pm="."><plain>3.19E-151 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="114" pm="."><plain>Dihydrofolate reductase </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="115" pm="."><plain>1.5.1.3 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="116" pm="."><plain>Glycinamide Ribonucleotide Formyltransferase Inhibitor </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="117" pm="."><plain>1.02E-134 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="118" pm="."><plain>Catechol O-methyltransferase </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="119" pm="."><plain>2.1.1.6 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="120" pm="."><plain>S-Adenosyl-L-Homocysteine Hydrolase Inhibitor </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="121" pm="."><plain>4.67E-127 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="122" pm="."><plain>Prostaglandin-endoperoxide synthase </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="123" pm="."><plain>1.14.99.1 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="124" pm="."><plain>Prostaglandin </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="125" pm="."><plain>8.57E-110 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="126" pm="."><plain>Purine-nucleoside phosphorylase </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="127" pm="."><plain>2.4.2.1 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="128" pm="."><plain>Adenosine (A1) Agonist </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="129" pm="."><plain>8.35E-105 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="130" pm="."><plain>Ribose-phosphate pyrophosphokinase </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="131" pm="."><plain>2.7.6.1 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="132" pm="."><plain>S-Adenosyl-L-Homocysteine Hydrolase Inhibitor </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="133" pm="."><plain>4.33E-91 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="134" pm="."><plain>Phosphoribosylglycinamide formyltransferase </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="135" pm="."><plain>2.1.2.2 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="136" pm="."><plain>Glycinamide Ribonucleotide Formyltransferase Inhibitor </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="137" pm="."><plain>1.55E-82 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="138" pm="."><plain>Phosphoribosylaminoimidazolecarboxamide formyltransferase </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="139" pm="."><plain>2.1.2.3 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="140" pm="."><plain>Glycinamide Ribonucleotide Formyltransferase Inhibitor </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="141" pm="."><plain>9.12E-80 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="142" pm="."><plain>3′,5′-cyclic-nucleotide phosphodiesterase </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="143" pm="."><plain>3.1.4.17 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="144" pm="."><plain>S-Adenosyl-L-Homocysteine Hydrolase Inhibitor </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="145" pm="."><plain>1.23E-77 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="146" pm="."><plain>Thymidylate synthase </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="147" pm="."><plain>2.1.1.45 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="148" pm="."><plain>Thymidylate Synthetase Inhibitor </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="149" pm="."><plain>2.54E-75 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="150" pm="."><plain>Steryl-sulfatase </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="151" pm="."><plain>3.1.6.2 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="152" pm="."><plain>Aromatase Inhibitor </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="153" pm="."><plain>4.90E-62 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="154" pm="."><plain>Guanylate cyclase </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="155" pm="."><plain>4.6.1.2 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="156" pm="."><plain>Purine Nucleoside Phosphorylase Inhibitor </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="157" pm="."><plain>2.68E-60 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="158" pm="."><plain>Cholestenone 5-alpha-reductase </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="159" pm="."><plain>1.3.1.22 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="160" pm="."><plain>Steroid (5alpha) Reductase Inhibitor </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="161" pm="."><plain>3.63E-60 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="162" pm="."><plain>Steroid 17-alpha-monooxygenase </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="163" pm="."><plain>1.14.99.9 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="164" pm="."><plain>Steroid (5alpha) Reductase Inhibitor </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="165" pm="."><plain>1.37E-58 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="166" pm="."><plain>RNA-directed DNA polymerase </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="167" pm="."><plain>2.7.7.49 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="168" pm="."><plain>S-Adenosyl-L-Homocysteine Hydrolase Inhibitor </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="169" pm="."><plain>1.06E-52 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="170" pm="."><plain>Alpha-glucosidase </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="171" pm="."><plain>3.2.1.20 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="172" pm="."><plain>Glucosidase (alpha) Inhibitor </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="173" pm="."><plain>1.00E-51 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="174" pm="."><plain>Farnesyl-diphosphate farnesyltransferase </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="175" pm="."><plain>2.5.1.21 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="176" pm="."><plain>Squalene Synthase Inhibitor </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="177" pm="."><plain>2.12E-46 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="178" pm="."><plain>Beta-galactosidase </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="179" pm="."><plain>3.2.1.23 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="180" pm="."><plain>Glucosidase (alpha) Inhibitor </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="181" pm="."><plain>4.04E-46 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="182" pm="."><plain>Sterol esterase </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="183" pm="."><plain>3.1.1.13 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="184" pm="."><plain>Phospholipase A2 Inhibitor </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="185" pm="."><plain>3.18E-44 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="186" pm="."><plain>Leukotriene-A4 hydrolase </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="187" pm="."><plain>3.3.2.6 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="188" pm="."><plain>Prostaglandin </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="189" pm="."><plain>5.16E-40 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="190" pm="."><plain>Squalene monooxygenase </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="191" pm="."><plain>1.14.99.7 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="192" pm="."><plain>Squalene Synthase Inhibitor </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="193" pm="."><plain>7.59E-40 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="194" pm="."><plain>Ribonucleoside-diphosphate reductase </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="195" pm="."><plain>1.17.4.1 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="196" pm="."><plain>S-Adenosyl-L-Homocysteine Hydrolase Inhibitor </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="197" pm="."><plain>2.47E-38 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="198" pm="."><plain>3-hydroxyanthranilate 3,4-dioxygenase </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="199" pm="."><plain>1.13.11.6 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="200" pm="."><plain>3-Hydroxyanthranilate Oxygenase Inhibitor </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="201" pm="."><plain>1.14E-33 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="202" pm="."><plain>Dihydroorotase </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="203" pm="."><plain>3.5.2.3 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="204" pm="."><plain>Dihydroorotase Inhibitor </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="205" pm="."><plain>2.25E-32 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="206" pm="."><plain>Nitric-oxide synthase </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="207" pm="."><plain>1.14.13.39 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="208" pm="."><plain>Nitric Oxide Synthase Inhibitor </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="209" pm="."><plain>8.86E-28 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="210" pm="."><plain>Phospholipase A2 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="211" pm="."><plain>3.1.1.4 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="212" pm="."><plain>Phospholipase A2 Inhibitor </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="213" pm="."><plain>9.82E-26 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="214" pm="."><plain>Diaminopimelate epimerase </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="215" pm="."><plain>5.1.1.7 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="216" pm="."><plain>Nitric Oxide Synthase Inhibitor </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="217" pm="."><plain>2.43E-24 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="218" pm="."><plain>Membrane dipeptidase </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="219" pm="."><plain>3.4.13.19 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="220" pm="."><plain>Nitric Oxide Synthase Inhibitor </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="221" pm="."><plain>2.81E-23 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="222" pm="."><plain>3-alpha(or 20-beta)-hydroxysteroid dehydrogenase </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="223" pm="."><plain>1.1.1.53 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="224" pm="."><plain>Aromatase Inhibitor </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="225" pm="."><plain>1.51E-22 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="226" pm="."><plain>Sterol O-acyltransferase </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="227" pm="."><plain>2.3.1.26 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="228" pm="."><plain>Adenosine (A2) Agonist </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="229" pm="."><plain>4.95E-22 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="230" pm="."><plain>Hydroxymethylglutaryl-CoA reductase (NADPH) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="231" pm="."><plain>1.1.1.34 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="232" pm="."><plain>Adenosine (A2) Agonist </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="233" pm="."><plain>4.95E-22 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="234" pm="."><plain>IMP dehydrogenase </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="235" pm="."><plain>1.1.1.205 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="236" pm="."><plain>Adenosine (A1) Agonist </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="237" pm="."><plain>8.98E-17 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="238" pm="."><plain>ATP-citrate (pro-S-)-lyase </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="239" pm="."><plain>4.1.3.8 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="240" pm="."><plain>Adenosine (A2) Agonist </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="241" pm="."><plain>1.83E-15 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="242" pm="."><plain>Glutamate–cysteine ligase </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="243" pm="."><plain>6.3.2.2 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="244" pm="."><plain>Nitric Oxide Synthase Inhibitor </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="245" pm="."><plain>2.71E-11 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="246" pm="."><plain>Dopamine-beta-monooxygenase </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="247" pm="."><plain>1.14.17.1 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="248" pm="."><plain>Adrenergic (beta1) Agonist </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="249" pm="."><plain>3.81E-11 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="250" pm="."><plain>Lanosterol synthase </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="251" pm="."><plain>5.4.99.7 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="252" pm="."><plain>Squalene Synthase Inhibitor </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="253" pm="."><plain>1.38E-10 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="254" pm="."><plain>Nucleoside-diphosphate kinase </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="255" pm="."><plain>2.7.4.6 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="256" pm="."><plain>P2T Purinoreceptor Antagonist </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="257" pm="."><plain>2.76E-10 </plain></SENT>
</text></td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt101"><label>a</label><p><text><SENT sid="258" pm="."><plain>Exact matches (the enzyme is the canonical target of the best MDDR hit) are shown in bold type, pathway matches (the enzyme shares the same pathway as the canonical target of the best MDDR hit) are shown in italic type, and enzymes not in the same pathway as the canonical target are shown in regular type. </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag><p><text><SENT sid="259" pm="."><plain>Other links recovered off-pathway hits, which often reflect known polypharmacology that is well-documented. </plain></SENT>
<SENT sid="260" pm="."><plain>For example, the glycinamide ribonucleotide formyltransferase (GART) inhibitor drug set hits both the GART reaction set (E = 1.55×10−82) and the off-pathway but pharmacologically related antifolate target dihydrofolate reductase (DHFR) (E = 1.02×10−134). </plain></SENT>
<SENT sid="261" pm="."><plain>Other off-pathway hits reflect biological connections, or physical connections, between targets. </plain></SENT>
<SENT sid="262" pm="."><plain>For example, the adenosine deaminase reaction set links to the A1 adenosine receptor agonist drug set (E = 7.69×10−159) ( Table 1 ) capturing the known interaction between A1 adenosine receptors and adenosine deaminase on the cell surface of smooth muscle cells [33]. </plain></SENT>
<SENT sid="263" pm="."><plain>Considering only the stringent case of exact matches based on EC numbers, a Mann-Whitney rank-sum test (also referred to as the U-test) shows that the expectation values for links between reaction sets and drug sets of known drug target enzymes were significantly better than the expectation values for links to reaction sets of non-target enzymes, i.e., 62 known enzyme targets were recovered in a background of 4,920 non-target “other” enzymes at a statistical significance of P = 2.01×10−6. </plain></SENT>
</text></p><p><text><SENT sid="264" pm="."><plain>In addition to recapitulating many known drug-target interactions, the links identified by these comparisons also suggest new hypotheses about drug-target interactions. </plain></SENT>
<SENT sid="265" pm="."><plain>One such new prediction involves the phospholipase A2 (PLA2) inhibitor drug class. </plain></SENT>
<SENT sid="266" pm="."><plain>The substrates and products of PLA2 recapitulate its known link to the PLA2 inhibitor drug set (E = 9.82×10−26), however, the sterol esterase reaction returns an even better score against the PLA2 inhibitor set (E = 3.18×10−44) ( Table 1 ). </plain></SENT>
<SENT sid="267" pm="."><plain>Although this predicted pharmacological relationship has, to our knowledge, not been previously documented, the result is consistent with the known biological relationship between PLA2 and sterol esterase. </plain></SENT>
<SENT sid="268" pm="."><plain>Both enzymes are secreted by the pancreas and require phosphatidylcholine hydrolysis to facilitate intestinal cholesterol uptake [34]. </plain></SENT>
<SENT sid="269" pm="."><plain>Thus, this link suggests that therapeutic agents directed against PLA2 may also inhibit sterol esterase, perhaps even more strongly than their intended target. </plain></SENT>
</text></p></sec><sec id="s2b"><title><text><SENT sid="270" pm="."><plain>Human drug “effect-space” maps detail interactions between drug classes and enzyme targets </plain></SENT>
</text></title><p><text><SENT sid="271" pm="."><plain>To present links between small molecule metabolites and drugs in the context of their known (and potential) metabolic targets, metabolic “effect-space” maps for currently marketed drugs were generated for each of the 246 drug classes investigated in this work. </plain></SENT>
<SENT sid="272" pm="."><plain>These maps enable visualization of the chemical similarities between drugs and metabolites painted onto human metabolic pathways, illustrating potential interactions between an individual drug class and specific metabolic enzymes in humans. </plain></SENT>
<SENT sid="273" pm="."><plain>Examples include the nucleoside reverse transcriptase, dihydrofolate reductase, and thymidylate synthase inhibitors which target pyrimidine nucleotide metabolism and biosynthesis of the essential coenzyme folate ( Figure 3   and   Table 2 ). </plain></SENT>
<SENT sid="274" pm="."><plain>Using the canonical human metabolic pathways from HumanCyc [35], a subset of the BioCyc [12] database collection, reactions in each metabolic network have been colored according to their similarity to known drug classes ( Figure 3 ). </plain></SENT>
<SENT sid="275" pm="."><plain>While  Table 1  presents only the top link for each of 62 enzyme targets in MetaCyc against the 246 MDDR drug classes, the networks in  Figure 3  detail all significant hits for selected drug classes against the pyrimidine and folate pathways. </plain></SENT>
<SENT sid="276" pm="."><plain>Interactive versions of these maps, one for each of the 246 drug classes included in our analysis, are available online (see below). </plain></SENT>
</text></p><SecTag type="FIG"><fig id="pcbi-1000474-g003" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1000474.g003</object-id><label>Figure 3</label><caption><title><text><SENT sid="277" pm="."><plain>Effect-space map showing chemical similarity between specific drug classes and metabolites in human folate and pyrimidine biosynthesis. </plain></SENT>
</text></title><p><text><SENT sid="278" pm="."><plain>Each node represents one reaction set – the substrates and products of a single human metabolic reaction. </plain></SENT>
<SENT sid="279" pm="."><plain>Edges connect the reactions in the canonical pathway as annotated in HumanCyc [35]. </plain></SENT>
<SENT sid="280" pm="."><plain>As given in the color key, each reaction is colored according to the expectation value indicating the strength of similarity between that target reaction set and the respective MDDR drug set. </plain></SENT>
<SENT sid="281" pm="."><plain>Diamond shaped nodes indicate reactions catalyzed by enzymes annotated as known drug targets in the MDDR; circles indicate reactions catalyzed by enzymes not annotated as targets. </plain></SENT>
<SENT sid="282" pm="."><plain>Reaction key: 1. </plain></SENT>
<SENT sid="283" pm="."><plain>Deoxyuridine kinase 2. </plain></SENT>
<SENT sid="284" pm="."><plain>Thymidine kinase 3. </plain></SENT>
<SENT sid="285" pm="."><plain>Thymidylate kinase 4. </plain></SENT>
<SENT sid="286" pm="."><plain>Deoxythymidine diphosphate kinase 5. </plain></SENT>
<SENT sid="287" pm="."><plain>Thymidylate synthase (TS) 6. </plain></SENT>
<SENT sid="288" pm="."><plain>Methylene tetrahydrofolate reductase 7. </plain></SENT>
<SENT sid="289" pm="."><plain>Dihydrofolate reductase (DHFR) 8. </plain></SENT>
<SENT sid="290" pm="."><plain>Deoxyuridine diphosphate kinase 9. </plain></SENT>
<SENT sid="291" pm="."><plain>Deoxyuridine triphosphate diphosphatase. </plain></SENT>
</text></p></caption><graphic xlink:href="pcbi.1000474.g003"/></fig></SecTag><SecTag type="TABLE"><table-wrap id="pcbi-1000474-t002" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1000474.t002</object-id><label>Table 2</label><caption><title><text><SENT sid="292" pm="."><plain>Links between selected drug classes and top ranked metabolic reactions. </plain></SENT>
</text></title></caption><alternatives><graphic id="pcbi-1000474-t002-2" xlink:href="pcbi.1000474.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><tbody><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="293" pm="."><plain>Rank </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="294" pm="."><plain>Thymidylate Synthetase (TS) Inhibitor </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="295" pm="."><plain>E-value </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="296" pm="."><plain>1 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="297" pm="."><plain>Dihydrofolate reductase (DHFR) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="298" pm="."><plain>1.96E-123 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="299" pm="."><plain>2 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="300" pm="."><plain>Methyltetrahydrofolate-corrinoid-iron-sulfur protein methyltransferase </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="301" pm="."><plain>3.58E-102 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="302" pm="."><plain>3 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="303" pm="."><plain>Methionyl-tRNA formyltransferase </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="304" pm="."><plain>1.97E-99 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="305" pm="."><plain>4 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="306" pm="."><plain>Methylenetetrahydrofolate reductase </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="307" pm="."><plain>2.67E-86 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="308" pm="."><plain>5 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="309" pm="."><plain>Thymidylate synthase (TS) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="310" pm="."><plain>2.54E-75 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="311" pm="."><plain>6 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="312" pm="."><plain>Formate-tetrahydrofolate ligase </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="313" pm="."><plain>1.44E-74 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="314" pm="."><plain>7 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="315" pm="."><plain>Dihydrofolate synthetase </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="316" pm="."><plain>1.35E-70 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="317" pm="."><plain>8 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="318" pm="."><plain>Aminomethyltransferase </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="319" pm="."><plain>7.13E-63 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="320" pm="."><plain>9 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="321" pm="."><plain>5-methyltetrahydrofolate-homocysteine S-methyltransferase </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="322" pm="."><plain>2.80E-62 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="323" pm="."><plain>10 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="324" pm="."><plain>Phosphoribosylaminoimidazolecarboxamide (AICAR) formyltransferase </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="325" pm="."><plain>1.50E-60 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="326" pm="."><plain>11 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="327" pm="."><plain>Phosphoribosylglycinamide formyltransferase (GART) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="328" pm="."><plain>1.50E-60 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="329" pm="."><plain>Rank </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="330" pm="."><plain>Dihydrofolate Reductase (DHFR) Inhibitor </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="331" pm="."><plain>E-value </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="332" pm="."><plain>1 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="333" pm="."><plain>Dihydrofolate reductase (DHFR) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="334" pm="."><plain>1.46E-82 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="335" pm="."><plain>2 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="336" pm="."><plain>Methyltetrahydrofolate-corrinoid-iron-sulfur protein methyltransferase </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="337" pm="."><plain>2.84E-75 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="338" pm="."><plain>3 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="339" pm="."><plain>Methylenetetrahydrofolate reductase </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="340" pm="."><plain>6.01E-73 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="341" pm="."><plain>4 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="342" pm="."><plain>Methionyl-tRNA formyltransferase </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="343" pm="."><plain>7.00E-66 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="344" pm="."><plain>5 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="345" pm="."><plain>Aminomethyltransferase </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="346" pm="."><plain>6.90E-55 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="347" pm="."><plain>6 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="348" pm="."><plain>Formate-tetrahydrofolate ligase </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="349" pm="."><plain>6.15E-49 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="350" pm="."><plain>7 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="351" pm="."><plain>Thymidylate synthase (TS) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="352" pm="."><plain>1.91E-48 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="353" pm="."><plain>8 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="354" pm="."><plain>5-methyltetrahydrofolate-homocysteine S-methyltransferase </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="355" pm="."><plain>2.60E-45 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="356" pm="."><plain>9 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="357" pm="."><plain>3-methyl-2-oxobutanoate hydroxymethyltransferase </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="358" pm="."><plain>2.68E-44 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="359" pm="."><plain>10 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="360" pm="."><plain>Glycine decarboxylase </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="361" pm="."><plain>2.68E-44 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="362" pm="."><plain>11 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="363" pm="."><plain>Glycine hydroxymethyltransferase (SHMT) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="364" pm="."><plain>2.68E-44 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="365" pm="."><plain>12 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="366" pm="."><plain>Dihydrofolate synthetase </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="367" pm="."><plain>9.65E-42 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="368" pm="."><plain>13 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="369" pm="."><plain>Phosphoribosylaminoimidazolecarboxamide (AICAR) formyltransferase </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="370" pm="."><plain>2.21E-39 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="371" pm="."><plain>14 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="372" pm="."><plain>Phosphoribosylglycinamide formyltransferase (GART) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="373" pm="."><plain>2.21E-39 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="374" pm="."><plain>Rank </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="375" pm="."><plain>Nucleoside Reverse Transcriptase Inhibitor (NRTI) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="376" pm="."><plain>E-value </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="377" pm="."><plain>1 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="378" pm="."><plain>Thymidylate kinase </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="379" pm="."><plain>7.48E-28 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="380" pm="."><plain>2 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="381" pm="."><plain>Thymidine kinase </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="382" pm="."><plain>3.48E-26 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="383" pm="."><plain>3 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="384" pm="."><plain>Deoxythymidine diphosphate kinase </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="385" pm="."><plain>1.54E-24 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="386" pm="."><plain>4 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="387" pm="."><plain>Ribonucleoside-triphosphate reductase </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="388" pm="."><plain>2.88E-14 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="389" pm="."><plain>5 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="390" pm="."><plain>Deoxyuridine triphosphate pyrophosphatase </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="391" pm="."><plain>5.60E-12 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="392" pm="."><plain>6 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="393" pm="."><plain>Deoxyuridine kinase </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="394" pm="."><plain>1.14E-11 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="395" pm="."><plain>7 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="396" pm="."><plain>Deoxyuridine diphosphate kinase </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="397" pm="."><plain>1.45E-11 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="398" pm="."><plain>8 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="399" pm="."><plain>Thymidylate synthase (TS) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="400" pm="."><plain>5.68E-11 </plain></SENT>
</text></td></tr></tbody></table></alternatives></table-wrap></SecTag><p><text><SENT sid="401" pm="."><plain>It has previously been shown that chemical similarity between known drugs often suggests novel drug-target interactions [5]–[7],[14]. </plain></SENT>
<SENT sid="402" pm="."><plain>Consistent with these observations, effect-space maps such as those shown in  Figure 3  can also be used to exploit chemical similarities between drugs and metabolites to indicate potential routes of drug metabolism and toxicity [3],[11],[36],[37]. </plain></SENT>
<SENT sid="403" pm="."><plain>For example, the nucleotide reverse transcriptase inhibitors (NRTIs) used in HIV therapy are administered as pro-drugs. </plain></SENT>
<SENT sid="404" pm="."><plain>The effect-space map reflects this route of NRTI metabolism leading to viral inhibition. </plain></SENT>
<SENT sid="405" pm="."><plain>The top three hits yielded by the NRTI drug set queried against human metabolism – thymidine kinase (E = 3.48×10−26), thymidylate kinase (E = 7.48×10−28), and deoxythymidine diphosphate kinase (E = 1.54×10−24) ( Figure 3  reaction numbers 2, 3, and 4; additional results in  Table 2 ) – successively phosphorylate the NRTI pro-drugs into the pharmacologically active NRTI triphosphates [38],[39]. </plain></SENT>
<SENT sid="406" pm="."><plain>The viral reverse transcriptase enzyme then incorporates the fully phosphorylated NRTIs into the growing DNA strand, thereby terminating transcription of the viral DNA. </plain></SENT>
<SENT sid="407" pm="."><plain>In this example, considerable toxicity mitigates the therapeutic value of inhibiting viral DNA transcription since the phosphorylated NRTIs directly inhibit human nucleotide kinases and mitochondrial DNA pol-γ. </plain></SENT>
<SENT sid="408" pm="."><plain>They also may be incorporated by pol-γ into the growing human mitochondrial DNA strand, and once incorporated are inefficiently excised by DNA pol-γ exonuclease [40]. </plain></SENT>
<SENT sid="409" pm="."><plain>Thus, the effect-space map illustrates both the route of metabolism and a mechanism of toxicity for NRTIs in humans. </plain></SENT>
</text></p><p><text><SENT sid="410" pm="."><plain>Drug effect-space maps also offer a broad glimpse of potential human metabolic interactions predicting new “polypharmacology”. </plain></SENT>
<SENT sid="411" pm="."><plain>From the ligand perspective, “drug polypharmacology” refers to a single drug or drug class that hits multiple targets. </plain></SENT>
<SENT sid="412" pm="."><plain>For example, dihydrofolate reductase (DHFR, reaction number 7 in  Figure 3 ) uses NADPH to reduce 7,8-dihydrofolate to tetrahydrofolate. </plain></SENT>
<SENT sid="413" pm="."><plain>Antifolate drugs inhibit DHFR, and, as expected, the DHFR drug set recovers the DHFR reaction substrates and products as the top similarity hit in human metabolism (E = 1.46×10−82) ( Figure 3 ,  Table 2 ,  Figure 4 ). </plain></SENT>
<SENT sid="414" pm="."><plain>However, at least 20 other reactions also use folate coenzymes in human metabolism [41]–[43]. </plain></SENT>
<SENT sid="415" pm="."><plain>Accordingly, SEA finds additional links between the DHFR drug set and established antifolate targets outside the pyrimidine and folate biosynthesis pathways such as serine hydroxymethyltransferase (SHMT, E = 2.68×10−44), phosphoribosyl-aminoimidazole-carboxamide formyltransferase (AICAR transformylase, E = 2.21×10−39), and phosphoribosyl-glycinamide formyltransferase (GART, E = 2.21×10−39) ( Table 2 ). </plain></SENT>
<SENT sid="416" pm="."><plain>The effect-space maps in  Figure 3  illustrate the results from  Table 2  and  Figure 4  in a single view, illustrating drug polypharmacology with respect to critical metabolic pathways. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="pcbi-1000474-g004" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1000474.g004</object-id><label>Figure 4</label><caption><title><text><SENT sid="417" pm="."><plain>Selected links between MDDR drug classes and human folate and pyrimidine metabolism. </plain></SENT>
</text></title></caption><graphic xlink:href="pcbi.1000474.g004"/></fig></SecTag><p><text><SENT sid="418" pm="."><plain>Alternatively, from the target perspective, “target polypharmacology” may refer to a single target being modulated by multiple classes of drugs. </plain></SENT>
<SENT sid="419" pm="."><plain>For instance, thymidylate synthase (TS) is another classic antifolate target that uses a folate coenzyme to methylate deoxyuridine phosphate, generating deoxythymidine phosphate [44]–[47]. </plain></SENT>
<SENT sid="420" pm="."><plain>As expected, the TS reaction links to known antifolate drug classes such as GART inhibitors (E = 4.76×10−73) and DHFR inhibitors (E = 1.91×10−48) ( Table 3   and   Figure 4 ). </plain></SENT>
<SENT sid="421" pm="."><plain>However, TS is also effectively inhibited by uracil analogs such as fluoropropynyl deoxyuridine, which is not a folate, but rather a pyrimidine analog. </plain></SENT>
<SENT sid="422" pm="."><plain>Accordingly, the TS reaction also links to reverse transcriptase inhibitors, which include fluoropropynyl deoxyuridine and additional pyrimidine analogs such as azidothymidine (AZT) (E = 5.68×10−11) ( Figure 4 ). </plain></SENT>
<SENT sid="423" pm="."><plain>The target polypharmacology of the thymidylate synthase enzyme is mirrored by the drug polypharmacology of the thymidylate synthase inhibitors. </plain></SENT>
<SENT sid="424" pm="."><plain>The TS inhibitors link not only to the reactions of deoxyribonucleotide biosynthesis including thymidylate synthase (E = 2.54×10−75), but also the GART (E = 1.50×10−60) and DHFR (E = 1.96×10−123) reactions ( Figure 3   and   Table 2 ). </plain></SENT>
<SENT sid="425" pm="."><plain>Thus, SEA recapitulates the known polypharmacology of TS. </plain></SENT>
<SENT sid="426" pm="."><plain>Effect-space maps illustrate and clarify these pharmacological relationships. </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="pcbi-1000474-t003" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1000474.t003</object-id><label>Table 3</label><caption><title><text><SENT sid="427" pm="."><plain>Links between selected metabolic reactions and top ranked drug classes. </plain></SENT>
</text></title></caption><alternatives><graphic id="pcbi-1000474-t003-3" xlink:href="pcbi.1000474.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><tbody><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="428" pm="."><plain>Rank </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="429" pm="."><plain>Thymidylate Synthetase (TS) Reaction </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="430" pm="."><plain>E-value </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="431" pm="."><plain>1 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="432" pm="."><plain>Thymidylate synthase inhibitor (TS) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="433" pm="."><plain>2.54E-75 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="434" pm="."><plain>2 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="435" pm="."><plain>Glycinamide ribonucleotide formyltransferase inhibitor (GART) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="436" pm="."><plain>4.76E-73 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="437" pm="."><plain>3 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="438" pm="."><plain>Thymidine kinase inhibitor (TK) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="439" pm="."><plain>1.18E-62 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="440" pm="."><plain>4 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="441" pm="."><plain>Dihydrofolate reductase inhibitor (DHFR) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="442" pm="."><plain>1.91E-48 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="443" pm="."><plain>5 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="444" pm="."><plain>Folylpolyglutamate synthetase inhibitor </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="445" pm="."><plain>2.27E-31 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="446" pm="."><plain>6 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="447" pm="."><plain>Nucleoside reverse transcriptase inhibitor (NRTI) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="448" pm="."><plain>5.68E-11 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="449" pm="."><plain>Rank </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="450" pm="."><plain>Dihydrofolate Reductase (DHFR) Reaction </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="451" pm="."><plain>E-value </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="452" pm="."><plain>1 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="453" pm="."><plain>Glycinamide Ribonucleotide Formyltransferase Inhibitor </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="454" pm="."><plain>1.02E-134 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="455" pm="."><plain>2 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="456" pm="."><plain>Thymidylate Synthetase Inhibitor </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="457" pm="."><plain>1.96E-123 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="458" pm="."><plain>3 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="459" pm="."><plain>Dihydrofolate Reductase Inhibitor </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="460" pm="."><plain>1.46E-82 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="461" pm="."><plain>4 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="462" pm="."><plain>Folylpolyglutamate Synthetase Inhibitor </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="463" pm="."><plain>3.15E-62 </plain></SENT>
</text></td></tr></tbody></table></alternatives></table-wrap></SecTag></sec><sec id="s2c"><title><text><SENT sid="464" pm="."><plain>Species-specific effect-space maps for pathogens and model organisms </plain></SENT>
</text></title><p><text><SENT sid="465" pm="."><plain>The great diversity of metabolic strategies, pathways, and enzymes present in humans, model organisms, and pathogenic species presents both opportunities and significant barriers to drug discovery. </plain></SENT>
<SENT sid="466" pm="."><plain>To address these issues, species-specific effect-space maps were created for each of 385 organisms from the BioCyc Database Collection. </plain></SENT>
<SENT sid="467" pm="."><plain>Target reactions existing in common and differentially between each of these species and humans are shown in these metabolic maps. </plain></SENT>
<SENT sid="468" pm="."><plain>As with the human effect-space maps, this set of maps is available in interactive form online. </plain></SENT>
<SENT sid="469" pm="."><plain>To show how these maps may be used to provide a context for drug discovery, MRSA is used as an example ( Figure 5 ). </plain></SENT>
<SENT sid="470" pm="."><plain>The global view of drugs and metabolism provided by this species-specific map illustrates some of the daunting challenges to the selection of tractable metabolic drug targets in this organism. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="pcbi-1000474-g005" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1000474.g005</object-id><label>Figure 5</label><caption><title><text><SENT sid="471" pm="."><plain>Effect-space map showing chemical similarity between drugs and metabolites in MRSA. </plain></SENT>
</text></title><p><text><SENT sid="472" pm="."><plain>Canonical pathway representation of methicillin-resistant Staphylococcus aureus (MRSA) [12] small molecule metabolism colored by expectation value of the best hit against MDDR. </plain></SENT>
<SENT sid="473" pm="."><plain>Reactions that are also present in humans have been faded. </plain></SENT>
<SENT sid="474" pm="."><plain>Layout based upon the Cytoscape 2.5 y-files hierarchical layout. </plain></SENT>
<SENT sid="475" pm="."><plain>Edge lengths are not significant. </plain></SENT>
<SENT sid="476" pm="."><plain>For ease of viewing, reactions are not labeled but can be identified in the interactive versions of the maps available at the online resource. </plain></SENT>
</text></p></caption><graphic xlink:href="pcbi.1000474.g005"/></fig></SecTag><p><text><SENT sid="477" pm="."><plain>As described for  Figure 3 , each node in the MRSA network in  Figure 5  represents one reaction set, the substrates and products of a single metabolic reaction. </plain></SENT>
<SENT sid="478" pm="."><plain>Edges connect the reactions according to canonical BioCyc MRSA pathways. </plain></SENT>
<SENT sid="479" pm="."><plain>Each reaction in the network has been colored according the expectation value of the best link between the reaction set and any of the 246 MDDR drug sets. </plain></SENT>
<SENT sid="480" pm="."><plain>Lighter colored nodes have higher expectation values indicating less drug-like reaction sets, while darker colored nodes indicate more drug-like reaction sets. </plain></SENT>
<SENT sid="481" pm="."><plain>To provide therapeutic context, reactions that are also present in human metabolism have been faded, indicating that drug sets targeting these enzymes in MRSA may have the undesirable potential to inhibit the human enzymes as well. </plain></SENT>
<SENT sid="482" pm="."><plain>As with the other organisms represented in our online maps, most reactions in the MRSA subset have little chemical similarity to any MDDR drug set. </plain></SENT>
<SENT sid="483" pm="."><plain>Although 74% of the 469 MRSA metabolic reactions have measurable similarity to at least one MDDR drug set, only 36% of these links had expectation values of E = 1.0×10−10 or better. </plain></SENT>
<SENT sid="484" pm="."><plain>Several complete pathways of diverse chemical classes, including shikimic acid, phospholipid, peptidoglycan, teichoic acid, and molybdenum cofactor biosynthesis, lack links to any drug set at all. </plain></SENT>
<SENT sid="485" pm="."><plain>Only 18 of the 469 MRSA metabolic reactions are already known to be drug targets in MDDR. </plain></SENT>
<SENT sid="486" pm="."><plain>Fourteen of these are represented in  Figure 5  (as diamonds), but all 18 of these also appear in humans. </plain></SENT>
<SENT sid="487" pm="."><plain>Enzymes that catalyze these reactions in humans would likely be vulnerable to inhibitors developed against these MRSA targets, putting those drugs at risk for toxicity. </plain></SENT>
</text></p><p><text><SENT sid="488" pm="."><plain> Figure 6  illustrates how additional information can be used to further filter potential metabolic targets by painting additional biological or genomic data onto a species-specific map. </plain></SENT>
<SENT sid="489" pm="."><plain>Since successful modulation of a target may not alone be sufficient to kill a pathogen due to the presence of redundant pathways for the formation of critical metabolites, integration of such additional information into a metabolic map may provide added value in addressing the multi-dimensional challenges of drug discovery. </plain></SENT>
<SENT sid="490" pm="."><plain>Flux balance analysis of metabolic networks was used by several of the authors of this work to identify essential enzymes and metabolites required for the formation of all necessary biomass components for 13 strains of Staphylococcus aureus including the methicillin-resistant N315 strain (MRSA) [48]. </plain></SENT>
<SENT sid="491" pm="."><plain>Using these results, 39 essential reactions and 19 synthetic lethal reaction pairs could be mapped to our dataset ( Figure 6 ), highlighting those reactions for which inhibition is most likely to result in the death of the organism. </plain></SENT>
<SENT sid="492" pm="."><plain>Several of these reactions have been successfully targeted by currently marketed drugs, such as the previously discussed antifolate targets DHFR (E = 1.02×10−134), thymidylate synthase (E = 2.54×10−75), and dihydrofolate synthase (E = 1.35×10−70). </plain></SENT>
<SENT sid="493" pm="."><plain>This retrospective result illustrates the potential of such additional information in enriching for targets and drug chemistry that have been proven accessible. </plain></SENT>
<SENT sid="494" pm="."><plain>Other targets and pathways have not yet yielded successful drugs but are under investigation in MRSA or other pathogens, such as the shikimate pathway [49] in aromatic amino acid biosynthesis and the histidine biosynthesis pathway [50]. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="pcbi-1000474-g006" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1000474.g006</object-id><label>Figure 6</label><caption><title><text><SENT sid="495" pm="."><plain>Essential and synthetic lethal map of MRSA metabolism. </plain></SENT>
</text></title><p><text><SENT sid="496" pm="."><plain>Canonical pathway representation of methicillin-resistant Staphylococcus aureus (MRSA) small molecule metabolism colored by essentiality and synthetic lethality of reactions. </plain></SENT>
<SENT sid="497" pm="."><plain>Key: black = essential reaction; other colors = synthetic lethal reaction pairs; node size = similarity to top MDDR hit (bigger is more drug-like); diamond shape = MDDR drug target; faded border = human reaction. </plain></SENT>
</text></p></caption><graphic xlink:href="pcbi.1000474.g006"/></fig></SecTag><p><text><SENT sid="498" pm="."><plain>The combination of the essentiality data with the drug space mapping emphasizes the challenges to drug discovery against MRSA. </plain></SENT>
<SENT sid="499" pm="."><plain>Thus, while species-specific antifolates do exist, many antifolates such as methotrexate used in cancer therapy cause severe toxicity [43]. </plain></SENT>
<SENT sid="500" pm="."><plain>To avoid such toxicity, 14 of the 39 essential MRSA reactions that are also present in humans can be excluded from further consideration as drug targets in MRSA. </plain></SENT>
</text></p><p><text><SENT sid="501" pm="."><plain>A compilation of all of the metabolic network maps generated in this study is available at <ext-link ext-link-type="uri" xlink:href="http://sea.docking.org/metabolism">http://sea.docking.org/metabolism</ext-link>. </plain></SENT>
<SENT sid="502" pm="."><plain>These include interactive versions of the human effect-space maps shown in  Figure 3 , one for each of the 246 MDDR drug classes analyzed in this work, and 385 species-specific maps such as that shown in  Figure 5 . </plain></SENT>
<SENT sid="503" pm="."><plain>The species-specific maps were generated from the BioCyc database public collection, a compendium of 385 model organisms and pathogens whose genomes have been sequenced and their metabolomes deciphered. </plain></SENT>
<SENT sid="504" pm="."><plain>Of these, 65 have been designated as Priority Pathogens by the National Institute of Allergy and Infectious Diseases (NIAID) and include Bacillus anthracis, Brucella melitensis, Cryptosporidium parvum, Salmonella, SARS, Toxoplasma gondii, Vibrio cholerae, and Yersinia pestis [51]. </plain></SENT>
<SENT sid="505" pm="."><plain>Browse and similarity search tools are also provided, allowing exploration of the metabolic reaction sets and current drug classes used in this work, as well as comparison to user-defined custom ligand sets. </plain></SENT>
<SENT sid="506" pm="."><plain>These interactive tools enable facile exploration between the vast biological data on potential metabolic drug targets in these organisms and the drug chemistry currently available to prosecute those targets. </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="DISCUSS"><sec id="s3"><title><text><SENT sid="507" pm="."><plain>Discussion </plain></SENT>
</text></title><p><text><SENT sid="508" pm="."><plain>A key product of this study is the construction of drug-metabolite correspondence maps that provide both a global view and a more contextual picture of predicted drug action in human metabolism than has been previously available. </plain></SENT>
<SENT sid="509" pm="."><plain>Several aspects of these maps deserve particular emphasis. </plain></SENT>
<SENT sid="510" pm="."><plain>First, despite the differences in physiochemical properties of most drugs and small molecule metabolites, numerous links arise between drugs and metabolism. </plain></SENT>
<SENT sid="511" pm="."><plain>Viewed in the context of metabolic networks, the pharmacological relationships predicted by these links can be readily interpreted in a way that is biologically sensible. </plain></SENT>
<SENT sid="512" pm="."><plain>Moreover, as shown by both the drug effect space maps and species-specific maps, our retrospective analyses confirm that biologically and pharmacologically significant connections can be recovered, capturing known polypharmacology and revealing the relevant chemotypes previously explored in drug development. </plain></SENT>
<SENT sid="513" pm="."><plain>The metabolome-wide exploratory tools provided with these map sets also enable a new way to interrogate the links between drugs and metabolism that will likely be useful for prediction of new targets and to indicate routes of drug metabolism and toxicity. </plain></SENT>
<SENT sid="514" pm="."><plain>Further, by integrating biological information such as essentiality and synthetic lethal analyses with the metabolic context, our approach allows users to focus evaluation of potential targets around specific types of data simply by painting the results on to metabolic maps. </plain></SENT>
</text></p><p><text><SENT sid="515" pm="."><plain>With respect to the coverage of drug links across small molecule metabolism that this study provides, we note that the SEA method relies solely upon the chemical similarity of ligands to establish links between drug sets and reaction sets. </plain></SENT>
<SENT sid="516" pm="."><plain>Based on these links, and the biologically sensible connections shown in the results, we infer that a particular drug class may act on a certain target. </plain></SENT>
<SENT sid="517" pm="."><plain>However, drugs may also act against an enzyme active site without resembling the endogenous substrate, or by allosteric regulation at an entirely different site. </plain></SENT>
<SENT sid="518" pm="."><plain>The SEA method, as applied here to the substrates and products of metabolic reactions, does not capture these additional drug-target links. </plain></SENT>
<SENT sid="519" pm="."><plain>Other viable strategies are available for targeting metabolic enzyme active sites that use principles unrelated to the ligand-drug similarities that are the focus of our approach [52]–[55]. </plain></SENT>
<SENT sid="520" pm="."><plain>For instance, Tondi et al. designed novel inhibitors of thymidylate synthase that complemented the three dimensional structure of the active site. </plain></SENT>
<SENT sid="521" pm="."><plain>Five high-scoring compounds selected for testing were dissimilar to the substrate but bound competitively with it [55]. </plain></SENT>
<SENT sid="522" pm="."><plain>While many classical kinase inhibitors interact directly with the ATP binding site, imatinib (tradename Gleevec) represents a new generation of allosteric protein kinase inhibitors that alter the kinase conformation to prevent ATP binding. </plain></SENT>
<SENT sid="523" pm="."><plain>Other allosteric kinase inhibitors prevent the protein substrate from loading [52]. </plain></SENT>
</text></p><p><text><SENT sid="524" pm="."><plain>While a quantitative determination of the proportion of drug-target links that cannot be accessed by our approach is beyond the scope of this study, we can provide a rough estimate for the frequency of such cases based on the results reported in  Table 1 . </plain></SENT>
<SENT sid="525" pm="."><plain>Of the 62 known enzyme targets in MetaCyc, 42 (68%) the substrate/product metabolite sets show significant chemical similarity to at least one MDDR drug set, establishing a reasonable first pass estimate for the percentage of current enzyme targets accessible to this approach. </plain></SENT>
<SENT sid="526" pm="."><plain>Furthermore, 40% (2,044 of 5,056) of all MetaCyc reaction sets linked at E = 1.0×10−10 or better to MDDR, with each reaction linking to an average of just 2.8 MDDR drug sets. </plain></SENT>
<SENT sid="527" pm="."><plain>These results indicate broad and specific coverage of metabolism, and suggest that numerous additional enzyme targets may be accessible by the method presented here. </plain></SENT>
</text></p><sec id="s3a"><title><text><SENT sid="528" pm="."><plain>Conclusion </plain></SENT>
</text></title><p><text><SENT sid="529" pm="."><plain>Using the SEA method, we have shown that comparison between ligand sets representing MDDR drug classes and ligand sets representing the substrates and products of metabolic reactions yields statistically significant links between known drugs and enzyme targets. </plain></SENT>
<SENT sid="530" pm="."><plain>Because the method is based on chemical similarity and requires only information from these molecule sets rather than the sequence, structure or physiochemistry of the targets, this ligand-based approach is independent from, and complementary to, protein structure and sequence based methods. </plain></SENT>
<SENT sid="531" pm="."><plain>Our results also suggest the potential of this method for predicting previously unknown interactions between drug classes and metabolic targets, recovering routes of metabolism and toxicity in humans, and identifying potential drug targets (as well as challenges for target discovery) in emerging pathogens. </plain></SENT>
<SENT sid="532" pm="."><plain>Thus, by mapping the chemical diversity of drugs to small molecule metabolism using ligand topology, this work establishes a computational framework for ligand-based prediction of drug class action, metabolism, and toxicity. </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="METHODS"><sec id="s4"><title><text><SENT sid="533" pm="."><plain>Methods </plain></SENT>
</text></title><sec id="s4a"><title/><sec id="s4a1"><title><text><SENT sid="534" pm="."><plain>Compound sets </plain></SENT>
</text></title><p><text><SENT sid="535" pm="."><plain>All compounds, both drugs and metabolites, are represented using Daylight SMILES strings [29]. </plain></SENT>
<SENT sid="536" pm="."><plain>Sets comprised of isomers with unique compound names were retained, even though stereochemistry was later removed as part of the molecule fingerprinting process. </plain></SENT>
</text></p></sec><sec id="s4a2"><title><text><SENT sid="537" pm="."><plain>Ligand sets </plain></SENT>
</text></title><p><text><SENT sid="538" pm="."><plain>Reaction sets were extracted from the 8.15.2007 release of MetaCyc based upon the substrates and products annotated to each reaction. </plain></SENT>
<SENT sid="539" pm="."><plain>Two filters were applied. </plain></SENT>
<SENT sid="540" pm="."><plain>First, the ten most common metabolites based on the number of occurrences in the MetaCyc metabolic network were removed: water, ATP, ADP, NAD, pyrophosphate, NADH, carbon dioxide, AMP, glutamate, and pyruvate. </plain></SENT>
<SENT sid="541" pm="."><plain>Second, each reaction set was required to include at least two unique compounds, as indicated by a MetaCyc or a MDDR unique compound id. </plain></SENT>
</text></p></sec><sec id="s4a3"><title><text><SENT sid="542" pm="."><plain>Drug sets </plain></SENT>
</text></title><p><text><SENT sid="543" pm="."><plain>Drug sets were extracted from the MDDR, a compilation of about 169,000 drug-like ligands in 688 activity classes, each targeting a specific enzyme (designated by the Enzyme Commission (E.C.) number). </plain></SENT>
<SENT sid="544" pm="."><plain>The subset of this database for which mappings between enzymes and the MDDR drug classes were available was used. </plain></SENT>
<SENT sid="545" pm="."><plain>These mappings were based on a previous study that maps E.C. numbers, GPCRs, ion channels and nuclear receptors to MDDR activity classes [32]. </plain></SENT>
<SENT sid="546" pm="."><plain>Only sets containing five or more ligands were used. </plain></SENT>
<SENT sid="547" pm="."><plain>Salts and fragments were removed, ligand protonation was normalized and duplicate molecules were removed. </plain></SENT>
<SENT sid="548" pm="."><plain>Of the 688 targets in the MDDR, 97 were excluded as having too few ligands (&lt;5), and another 345 targets were excluded because their definitions did not describe a molecular target, e.g., drugs associated only with an annotation such as “Anticancer” were not used. </plain></SENT>
<SENT sid="549" pm="."><plain>The remaining 246 enzyme targets were together associated with a total of 65,241 unique ligands, with a median and mean of 124 and 289 drug ligands per target. </plain></SENT>
<SENT sid="550" pm="."><plain>For further details, see Keiser et al. [6]. </plain></SENT>
</text></p></sec><sec id="s4a4"><title><text><SENT sid="551" pm="."><plain>Set comparisons </plain></SENT>
</text></title><p><text><SENT sid="552" pm="."><plain>All pairs of ligands between any two sets were compared using a pair-wise similarity metric, which consists of a descriptor and a similarity criterion. </plain></SENT>
<SENT sid="553" pm="."><plain>For the similarity descriptor, standard two-dimensional topological fingerprints were computed using the Scitegic ECFP4 fingerprint [56]. </plain></SENT>
<SENT sid="554" pm="."><plain>The similarity criterion was the widely used Tanimoto coefficient (Tc) [57]. </plain></SENT>
<SENT sid="555" pm="."><plain>For set comparisons, all pair-wise Tcs between elements across sets were calculated, and those scoring above a threshold were summed, giving a raw score relating the two sets. </plain></SENT>
<SENT sid="556" pm="."><plain>The Tanimoto coefficient threshold of 0.32 was determined according to a previously published method based upon fit to an extreme value distribution [6]. </plain></SENT>
<SENT sid="557" pm="."><plain>A model for random similarity similar to that used by BLAST [58] was used to generate expectation values (E) which are used to describe the strengths of relationships discovered using this protocol [6]. </plain></SENT>
<SENT sid="558" pm="."><plain>All scores reported here are based upon the background distribution and cutoff scores generated using the drug sets extracted from the MDDR collection. </plain></SENT>
<SENT sid="559" pm="."><plain>For further details, see Keiser et al. [6]. </plain></SENT>
<SENT sid="560" pm="."><plain>Network visualization was performed in Cytoscape 2.6.2 [59] using the γ-files hierarchical layout algorithm. </plain></SENT>
</text></p></sec><sec id="s4a5"><title><text><SENT sid="561" pm="."><plain>MRSA essentiality and synthetic lethal analysis </plain></SENT>
</text></title><p><text><SENT sid="562" pm="."><plain>Essentiality and synthetic lethal data generated as described earlier [48]. </plain></SENT>
<SENT sid="563" pm="."><plain>Briefly, the metabolic network was reconstructed from the genome to include all reactions that have an active flux The essentiality of a given enzyme was then assessed by the effect of the removal of that enzyme on biomass production. </plain></SENT>
<SENT sid="564" pm="."><plain>Similarly, synthetic lethal pairs can be identified by systematic pairwise deletion of enzymes and recalculation of biomass production in an ideally rich medium. </plain></SENT>
</text></p></sec></sec></sec></SecTag><SecTag type="SUPPL"><sec sec-type="supplementary-material" id="s5"><title><text><SENT sid="565" pm="."><plain>Supporting Information </plain></SENT>
</text></title><supplementary-material content-type="local-data" id="pcbi.1000474.s001"><label>Dataset S1</label><caption><p><text><SENT sid="566" pm="."><plain>MetaCyc reaction sets </plain></SENT>
</text></p><p><text><SENT sid="567" pm="."><plain>(0.47 MB TXT) </plain></SENT>
</text></p></caption><media xlink:href="pcbi.1000474.s001.txt"><caption><p><text><SENT sid="568" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pcbi.1000474.s002"><label>Dataset S2</label><caption><p><text><SENT sid="569" pm="."><plain>SMILES describing the molecular strucutre of MetaCyc reaction substrates and products </plain></SENT>
</text></p><p><text><SENT sid="570" pm="."><plain>(0.25 MB TXT) </plain></SENT>
</text></p></caption><media xlink:href="pcbi.1000474.s002.txt"><caption><p><text><SENT sid="571" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pcbi.1000474.s003"><label>Dataset S3</label><caption><p><text><SENT sid="572" pm="."><plain>MDDR drug sets </plain></SENT>
</text></p><p><text><SENT sid="573" pm="."><plain>(0.51 MB TXT) </plain></SENT>
</text></p></caption><media xlink:href="pcbi.1000474.s003.txt"><caption><p><text><SENT sid="574" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pcbi.1000474.s004"><label>Dataset S4</label><caption><p><text><SENT sid="575" pm="."><plain>SMILES describing the molecular structure of MDDR ligands. </plain></SENT>
</text></p><p><text><SENT sid="576" pm="."><plain>(4.45 MB TXT) </plain></SENT>
</text></p></caption><media xlink:href="pcbi.1000474.s004.txt"><caption><p><text><SENT sid="577" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pcbi.1000474.s005"><label>Dataset S5</label><caption><p><text><SENT sid="578" pm="."><plain>E-values for links between MDDR drug sets and MetaCyc reaction sets </plain></SENT>
</text></p><p><text><SENT sid="579" pm="."><plain>(3.12 MB CSV) </plain></SENT>
</text></p></caption><media xlink:href="pcbi.1000474.s005.csv"><caption><p><text><SENT sid="580" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material></sec></SecTag></body><back><SecTag type="ACK_FUND"><ack><p><text4fund><text><SENT sid="581" pm="."><plain>We thank Elsevier MDL for the MDDR and Scitegic for PipelinePilot. </plain></SENT>
</text></text4fund></p></ack></SecTag><fn-group><fn fn-type="COI-statement"><p><text><SENT sid="582" pm="."><plain>The authors have declared that no competing interests exist. </plain></SENT>
</text></p></fn><SecTag type="ACK_FUND"><fn fn-type="financial-disclosure"><p><text4fund><text><SENT sid="583" pm="."><plain>This work was supported by National Institutes of Health (NIH) GM60595 to PCB and U01-AI070499 to OGW. </plain></SENT>
<SENT sid="584" pm="."><plain>MJK was supported by Training Grant GM67547 and a National Science Foundation graduate fellowship. </plain></SENT>
<SENT sid="585" pm="."><plain>D-SL was supported by NIH GA1070499-01. </plain></SENT>
<SENT sid="586" pm="."><plain>Tools used for visualization of metabolic networks and SEA links were created by the UCSF Resource for Biocomputing, Visualization, and Informatics (RBVI) supported by NIH P41 RR-01081. </plain></SENT>
<SENT sid="587" pm="."><plain>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. </plain></SENT>
</text></text4fund></p></fn></SecTag></fn-group><SecTag type="REF"><ref-list><title>References</title><ref id="pcbi.1000474-Johnson1"><text><SENT sid="588" pm="."><plain>1 JohnsonMLajinessMMaggioraG 1989 Molecular similarity: a basis for designing drug screening programs. Prog Clin Biol Res 291 167 171 2726840 </plain></SENT>
</text></ref><ref id="pcbi.1000474-Payne1"><text><SENT sid="589" pm="."><plain>2 PayneDJGwynnMNHolmesDJPomplianoDL 2007 Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov 6 29 40 17159923 </plain></SENT>
</text></ref><ref id="pcbi.1000474-Kramer1"><text><SENT sid="590" pm="."><plain>3 KramerJASagartzJEMorrisDL 2007 The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates. Nat Rev Drug Discov 6 636 649 17643090 </plain></SENT>
</text></ref><ref id="pcbi.1000474-Drews1"><text><SENT sid="591" pm="."><plain>4 DrewsJ 2006 Case histories, magic bullets and the state of drug discovery. Nat Rev Drug Discov 5 635 640 16883301 </plain></SENT>
</text></ref><ref id="pcbi.1000474-Paolini1"><text><SENT sid="592" pm="."><plain>5 PaoliniGVShaplandRHvan HoornWPMasonJSHopkinsAL 2006 Global mapping of pharmacological space. Nat Biotechnol 24 805 815 16841068 </plain></SENT>
</text></ref><ref id="pcbi.1000474-Keiser1"><text><SENT sid="593" pm="."><plain>6 KeiserMJRothBLArmbrusterBNErnsbergerPIrwinJJ 2007 Relating protein pharmacology by ligand chemistry. Nat Biotechnol 25 197 206 17287757 </plain></SENT>
</text></ref><ref id="pcbi.1000474-Cleves1"><text><SENT sid="594" pm="."><plain>7 ClevesAEJainAN 2006 Robust ligand-based modeling of the biological targets of known drugs. J Med Chem 49 2921 2938 16686535 </plain></SENT>
</text></ref><ref id="pcbi.1000474-Watkins1"><text><SENT sid="595" pm="."><plain>8 WatkinsSMGermanJB 2002 Metabolomics and biochemical profiling in drug discovery and development. Curr Opin Mol Ther 4 224 228 12139307 </plain></SENT>
</text></ref><ref id="pcbi.1000474-Shyur1"><text><SENT sid="596" pm="."><plain>9 ShyurLFYangNS 2008 Metabolomics for phytomedicine research and drug development. Curr Opin Chem Biol 12 66 71 18258212 </plain></SENT>
</text></ref><ref id="pcbi.1000474-Rochfort1"><text><SENT sid="597" pm="."><plain>10 RochfortS 2005 Metabolomics reviewed: a new “omics” platform technology for systems biology and implications for natural products research. J Nat Prod 68 1813 1820 16378385 </plain></SENT>
</text></ref><ref id="pcbi.1000474-Kell1"><text><SENT sid="598" pm="."><plain>11 KellDB 2006 Systems biology, metabolic modelling and metabolomics in drug discovery and development. Drug Discov Today 11 1085 1092 17129827 </plain></SENT>
</text></ref><ref id="pcbi.1000474-Caspi1"><text><SENT sid="599" pm="."><plain>12 CaspiRFoersterHFulcherCAKaipaPKrummenackerM 2008 The MetaCyc Database of metabolic pathways and enzymes and the BioCyc collection of Pathway/Genome Databases. Nucleic Acids Res 36 D623 631 17965431 </plain></SENT>
</text></ref><ref id="pcbi.1000474-Dobson1"><text><SENT sid="600" pm="."><plain>13 DobsonCM 2004 Chemical space and biology. Nature 432 824 828 15602547 </plain></SENT>
</text></ref><ref id="pcbi.1000474-Yildirim1"><text><SENT sid="601" pm="."><plain>14 YildirimMAGohKICusickMEBarabasiALVidalM 2007 Drug-target network. Nat Biotechnol 25 1119 1126 17921997 </plain></SENT>
</text></ref><ref id="pcbi.1000474-Yamanishi1"><text><SENT sid="602" pm="."><plain>15 YamanishiYArakiMGutteridgeAHondaWKanehisaM 2008 Prediction of drug-target interaction networks from the integration of chemical and genomic spaces. Bioinformatics 24 i232 240 18586719 </plain></SENT>
</text></ref><ref id="pcbi.1000474-Cheng1"><text><SENT sid="603" pm="."><plain>16 ChengACColemanRGSmythKTCaoQSoulardP 2007 Structure-based maximal affinity model predicts small-molecule druggability. Nat Biotechnol 25 71 75 17211405 </plain></SENT>
</text></ref><ref id="pcbi.1000474-Goh1"><text><SENT sid="604" pm="."><plain>17 GohKICusickMEValleDChildsBVidalM 2007 The human disease network. Proc Natl Acad Sci U S A 104 8685 8690 17502601 </plain></SENT>
</text></ref><ref id="pcbi.1000474-Hajduk1"><text><SENT sid="605" pm="."><plain>18 HajdukPJHuthJRTseC 2005 Predicting protein druggability. Drug Discov Today 10 1675 1682 16376828 </plain></SENT>
</text></ref><ref id="pcbi.1000474-Hopkins1"><text><SENT sid="606" pm="."><plain>19 HopkinsALGroomCR 2002 The druggable genome. Nat Rev Drug Discov 1 727 730 12209152 </plain></SENT>
</text></ref><ref id="pcbi.1000474-Imming1"><text><SENT sid="607" pm="."><plain>20 ImmingPSinningCMeyerA 2006 Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov 5 821 834 17016423 </plain></SENT>
</text></ref><ref id="pcbi.1000474-Meisner1"><text><SENT sid="608" pm="."><plain>21 MeisnerNCHintersteinerMUhlVWeidemannTSchmiedM 2004 The chemical hunt for the identification of drugable targets. Curr Opin Chem Biol 8 424 431 15338571 </plain></SENT>
</text></ref><ref id="pcbi.1000474-Russ1"><text><SENT sid="609" pm="."><plain>22 RussAPLampelS 2005 The druggable genome: an update. Drug Discov Today 10 1607 1610 16376820 </plain></SENT>
</text></ref><ref id="pcbi.1000474-Lee1"><text><SENT sid="610" pm="."><plain>23 LeeDSParkJKayKAChristakisNAOltvaiZN 2008 The implications of human metabolic network topology for disease comorbidity. Proc Natl Acad Sci U S A 105 9880 9885 18599447 </plain></SENT>
</text></ref><ref id="pcbi.1000474-Navarro1"><text><SENT sid="611" pm="."><plain>24 NavarroMBHuttnerBHarbarthS 2008 Methicillin-resistant Staphylococcus aureus control in the 21st century: beyond the acute care hospital. Curr Opin Infect Dis 21 372 379 18594289 </plain></SENT>
</text></ref><ref id="pcbi.1000474-Powell1"><text><SENT sid="612" pm="."><plain>25 PowellJPWenzelRP 2008 Antibiotic options for treating community-acquired MRSA. Expert Rev Anti Infect Ther 6 299 307 18588495 </plain></SENT>
</text></ref><ref id="pcbi.1000474-Clements1"><text><SENT sid="613" pm="."><plain>26 ClementsAHaltonKGravesNPettittAMortonA 2008 Overcrowding and understaffing in modern health-care systems: key determinants in meticillin-resistant Staphylococcus aureus transmission. Lancet Infect Dis 8 427 434 18582835 </plain></SENT>
</text></ref><ref id="pcbi.1000474-Avdic1"><text><SENT sid="614" pm="."><plain>27 AvdicECosgroveSE 2008 Management and control strategies for community-associated methicillin-resistant Staphylococcus aureus. Expert Opin Pharmacother 9 1463 1479 18518778 </plain></SENT>
</text></ref><ref id="pcbi.1000474-Nicasio1"><text><SENT sid="615" pm="."><plain>28 NicasioAMKutiJLNicolauDP 2008 The current state of multidrug-resistant gram-negative bacilli in North America. Pharmacotherapy 28 235 249 18225969 </plain></SENT>
</text></ref><ref id="pcbi.1000474-James1"><text><SENT sid="616" pm="."><plain>29 JamesCWeiningerDDelaneyJ 1992–2005 Daylight Theory Manual Mission Viejo, CA Daylight Chemical Information Systems Inc  </plain></SENT>
</text></ref><ref id="pcbi.1000474-MDL1"><text><SENT sid="617" pm="."><plain>30 MDL Information Systems I 2006 MDL Drug Data Report San Leandro, CA MDL Information Systems, Inc  </plain></SENT>
</text></ref><ref id="pcbi.1000474-Tipton1"><text><SENT sid="618" pm="."><plain>31 TiptonKF 1992 Enzyme Nomenclature: Recommendations of the Nomenclature Committee of the International Union of Biochemistry and Molecular Biology (IUBMB) New York NC-IUBMB  </plain></SENT>
</text></ref><ref id="pcbi.1000474-Schuffenhauer1"><text><SENT sid="619" pm="."><plain>32 SchuffenhauerAZimmermannJStoopRvan der VyverJJLecchiniS 2002 An ontology for pharmaceutical ligands and its application for in silico screening and library design. J Chem Inf Comput Sci 42 947 955 12132896 </plain></SENT>
</text></ref><ref id="pcbi.1000474-Ciruela1"><text><SENT sid="620" pm="."><plain>33 CiruelaFSauraCCanelaEIMallolJLluisC 1996 Adenosine deaminase affects ligand-induced signalling by interacting with cell surface adenosine receptors. FEBS Lett 380 219 223 8601428 </plain></SENT>
</text></ref><ref id="pcbi.1000474-Mackay1"><text><SENT sid="621" pm="."><plain>34 MackayKStarrJRLawnRMEllsworthJL 1997 Phosphatidylcholine hydrolysis is required for pancreatic cholesterol esterase- and phospholipase A2-facilitated cholesterol uptake into intestinal Caco-2 cells. J Biol Chem 272 13380 13389 9148961 </plain></SENT>
</text></ref><ref id="pcbi.1000474-Romero1"><text><SENT sid="622" pm="."><plain>35 RomeroPWaggJGreenMLKaiserDKrummenackerM 2005 Computational prediction of human metabolic pathways from the complete human genome. Genome Biol 6 R2 15642094 </plain></SENT>
</text></ref><ref id="pcbi.1000474-Martin1"><text><SENT sid="623" pm="."><plain>36 MartinRRoseDYuKBarrosS 2006 Toxicogenomics strategies for predicting drug toxicity. Pharmacogenomics 7 1003 1016 17054411 </plain></SENT>
</text></ref><ref id="pcbi.1000474-Ekins1"><text><SENT sid="624" pm="."><plain>37 EkinsSAndreyevSRyabovAKirillovERakhmatulinEA 2005 Computational prediction of human drug metabolism. Expert Opin Drug Metab Toxicol 1 303 324 16922645 </plain></SENT>
</text></ref><ref id="pcbi.1000474-Lewis1"><text><SENT sid="625" pm="."><plain>38 LewisW 2004 Cardiomyopathy, nucleoside reverse transcriptase inhibitors and mitochondria are linked through AIDS and its therapy. Mitochondrion 4 141 152 16120379 </plain></SENT>
</text></ref><ref id="pcbi.1000474-Petit1"><text><SENT sid="626" pm="."><plain>39 PetitFFromentyBOwenAEstaquierJ 2005 Mitochondria are sensors for HIV drugs. Trends Pharmacol Sci 26 258 264 15860373 </plain></SENT>
</text></ref><ref id="pcbi.1000474-Lewis2"><text><SENT sid="627" pm="."><plain>40 LewisWKohlerJJHosseiniSHHaaseCPCopelandWC 2006 Antiretroviral nucleosides, deoxynucleotide carrier and mitochondrial DNA: evidence supporting the DNA pol gamma hypothesis. Aids 20 675 684 16514297 </plain></SENT>
</text></ref><ref id="pcbi.1000474-Kisliuk1"><text><SENT sid="628" pm="."><plain>41 KisliukRL 2000 Synergistic interactions among antifolates. Pharmacol Ther 85 183 190 10739873 </plain></SENT>
</text></ref><ref id="pcbi.1000474-Faessel1"><text><SENT sid="629" pm="."><plain>42 FaesselHMSlocumHKRustumYMGrecoWR 1999 Folic acid-enhanced synergy for the combination of trimetrexate plus the glycinamide ribonucleotide formyltransferase inhibitor 4-[2-(2-amino-4-oxo-4,6,7,8-tetrahydro-3H-pyrimidino[5,4,6][1,4]thiazin -6-yl)-(S)-ethyl]-2,5-thienoylamino-L-glutamic acid (AG2034): comparison across sensitive and resistant human tumor cell lines. Biochem Pharmacol 57 567 577 9952321 </plain></SENT>
</text></ref><ref id="pcbi.1000474-Chan1"><text><SENT sid="630" pm="."><plain>43 ChanDCAndersonAC 2006 Towards species-specific antifolates. Curr Med Chem 13 377 398 16475929 </plain></SENT>
</text></ref><ref id="pcbi.1000474-Costi1"><text><SENT sid="631" pm="."><plain>44 CostiMPFerrariSVenturelliACaloSTondiD 2005 Thymidylate synthase structure, function and implication in drug discovery. Curr Med Chem 12 2241 2258 16178783 </plain></SENT>
</text></ref><ref id="pcbi.1000474-Gmeiner1"><text><SENT sid="632" pm="."><plain>45 GmeinerWH 2005 Novel chemical strategies for thymidylate synthase inhibition. Curr Med Chem 12 191 202 15638735 </plain></SENT>
</text></ref><ref id="pcbi.1000474-McGuire1"><text><SENT sid="633" pm="."><plain>46 McGuireJJ 2003 Anticancer antifolates: current status and future directions. Curr Pharm Des 9 2593 2613 14529544 </plain></SENT>
</text></ref><ref id="pcbi.1000474-Chu1"><text><SENT sid="634" pm="."><plain>47 ChuECallenderMAFarrellMPSchmitzJC 2003 Thymidylate synthase inhibitors as anticancer agents: from bench to bedside. Cancer Chemother Pharmacol 52 Suppl 1 S80 89 12819937 </plain></SENT>
</text></ref><ref id="pcbi.1000474-Lee2"><text><SENT sid="635" pm="."><plain>48 LeeDSBurdHLiuJAlmaasEWiestO 2009 Comparative genome-scale metabolic reconstruction and flux balance analysis of multiple Staphylococcus aureus genomes identify novel antimicrobial drug targets. J Bacteriol 191 4015 4024 19376871 </plain></SENT>
</text></ref><ref id="pcbi.1000474-Dias1"><text><SENT sid="636" pm="."><plain>49 DiasMVElyFPalmaMSde AzevedoWFJrBassoLA 2007 Chorismate synthase: an attractive target for drug development against orphan diseases. Curr Drug Targets 8 437 444 17348836 </plain></SENT>
</text></ref><ref id="pcbi.1000474-Cho1"><text><SENT sid="637" pm="."><plain>50 ChoYIoergerTRSacchettiniJC 2008 Discovery of novel nitrobenzothiazole inhibitors for Mycobacterium tuberculosis ATP phosphoribosyl transferase (HisG) through virtual screening. J Med Chem 51 5984 5992 18778048 </plain></SENT>
</text></ref><ref id="pcbi.1000474-Zhang1"><text><SENT sid="638" pm="."><plain>51 ZhangCCrastaOCammerSWillRKenyonR 2008 An emerging cyberinfrastructure for biodefense pathogen and pathogen-host data. Nucleic Acids Res 36 D884 891 17984082 </plain></SENT>
</text></ref><ref id="pcbi.1000474-Bogoyevitch1"><text><SENT sid="639" pm="."><plain>52 BogoyevitchMAFairlieDP 2007 A new paradigm for protein kinase inhibition: blocking phosphorylation without directly targeting ATP binding. Drug Discov Today 12 622 633 17706543 </plain></SENT>
</text></ref><ref id="pcbi.1000474-Ciulli1"><text><SENT sid="640" pm="."><plain>53 CiulliAAbellC 2007 Fragment-based approaches to enzyme inhibition. Curr Opin Biotechnol 18 489 496 17959370 </plain></SENT>
</text></ref><ref id="pcbi.1000474-Moore1"><text><SENT sid="641" pm="."><plain>54 MooreECHurlbertRBBossGRMassiaSP 1989 Inhibition of two enzymes in de novo purine nucleotide synthesis by triciribine phosphate (TCN-P). Biochem Pharmacol 38 4045 4051 2480792 </plain></SENT>
</text></ref><ref id="pcbi.1000474-Tondi1"><text><SENT sid="642" pm="."><plain>55 TondiDSlomczynskaUCostiMPWattersonDMGhelliS 1999 Structure-based discovery and in-parallel optimization of novel competitive inhibitors of thymidylate synthase. Chem Biol 6 319 331 10322126 </plain></SENT>
</text></ref><ref id="pcbi.1000474-Hert1"><text><SENT sid="643" pm="."><plain>56 HertJWillettPWiltonDJAcklinPAzzaouiK 2004 Comparison of topological descriptors for similarity-based virtual screening using multiple bioactive reference structures. Org Biomol Chem 2 3256 3266 15534703 </plain></SENT>
</text></ref><ref id="pcbi.1000474-Willett1"><text><SENT sid="644" pm="."><plain>57 WillettP 2006 Similarity-based virtual screening using 2D fingerprints. Drug Discov Today 11 1046 1053 17129822 </plain></SENT>
</text></ref><ref id="pcbi.1000474-Altschul1"><text><SENT sid="645" pm="."><plain>58 AltschulSFGishWMillerWMyersEWLipmanDJ 1990 Basic local alignment search tool. Jour Mol Biol 215 403 410 2231712 </plain></SENT>
</text></ref><ref id="pcbi.1000474-Shannon1"><text><SENT sid="646" pm="."><plain>59 ShannonPMarkielAOzierOBaligaNSWangJT 2003 Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 13 2498 2504 14597658 </plain></SENT>
</text></ref></ref-list></SecTag></back></article>
